Enveric Biosciences Inc
ENVB
Get informed when a big investor buys or sells
+ FollowMarket Cap$967.16K
Close$
$13.97
804.5% upside
Current Fair Value
804.5% upsideUndervalued by 804.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $967,159.00 |
|---|---|
| Enterprise Value | $-7,329,137.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-36.24 |
| Beta | 1.11 |
| Outstanding Shares | 3,987,084 |
Return
| Return on Equity | -126.72% |
|---|---|
| Return on Assets | -114.52% |
| Return on Invested Capital | -107.99% |
Valuation & Multiples
| P/E Ratio | -0.1 |
|---|---|
| PEG | -0.49 |
| Price to Sales | - |
| Price to Book Ratio | 0.77 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.84 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 13.23%▲ 9.59% |
|---|---|
| Total Invested | $733,605▲ 588.22% |
| Investors Holding | 24▲ 13.00% |
ESG Score
No data
About Enveric Biosciences Inc
3 employees
CEO: Brent Kelton Enveric Biosciences is a patient-first biotechnology company developing rigorously tested, novel cannabinoid medicines to improve quality of life for cancer patients. Initial indications include radiodermatitis, a common and often severe...